FDA expands omicron-specific COVID-19 booster vaccine authorization to children under 5
Pleasant on Weekly (Mon, Dec 12, 2022) – The U.S. Food and Drug Administration on Thursday expanded its authorization for the omicron-specific COVID-19 booster vaccine to include children under age 5.
Children between the ages of 6 months and 5 years who received the initial Moderna COVID-19 vaccine will become eligible for the Moderna booster if they completed their initial vaccine series at least two months prior.